Genomics-Driven Drug Trials Built To Be Fast And Flexible
This article was originally published in The Gray Sheet
Executive Summary
Pioneering next-generation sequencing enrollment strategies are coupled with adaptive statistical designs in the next wave of drug "basket" trials from NCI, ASCO and Novartis.